Tags

Type your tag names separated by a space and hit enter

The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Endocr Res. 2014; 39(4):189-93.ER

Abstract

Abstract Papillary carcinoma is the most prevalent malignancy of thyroid gland, and its incidence has been recently increased. The BRAF(V600E) mutation is the most frequent genetic alteration in papillary thyroid carcinoma (PTC). The role of BRAF(V600E) mutation as a potential prognostic factor has been controversially reported in different studies, with short-term follow-up. In this study, we evaluated the role of BRAF(V600E) mutation as a potential marker for prognostic stratification of patients with PTC in long-term follow-up. We studied 69 PTC patients with a mean follow-up period of 63.9 months (median: 60 m). The BRAF(V600E) mutation was analyzed by PCR-single-strand conformational polymorphism and sequencing. The correlation between the presence or absence of the BRAF(V600E) mutation, clinicopathological features and prognosis of PTC patients were studied. The BRAF(V600E) mutation was found in 28 of 69 (40.6%) PTC patients, and it was significantly more frequent in older patients (p < 0.001), in advanced tumor stages (p = 0.006) and in patients with history of radiation exposure (p = 0.037). Incomplete response to treatment in PTC patients was significantly correlated with certain clinicopathological characteristics (follow-up time, distant metastases, advanced stage, first thyroglobulin (fTg) level, history of reoperation and external radiotherapy and delay in iodine therapy) but it was not related to the presence of BRAF(V600E) mutation. Prevalence of BRAF(V600E) mutation was 40.6% in patients with papillary thyroid cancer in northeast of Iran. The BRAF(V600E) mutation was associated with older age and advanced tumor stage but was not correlated with incomplete response during follow-up.

Authors+Show Affiliations

Surgical Oncology Research Center, Emam Reza Hospital, Faculty of Medicine .No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24679337

Citation

Daliri, Mahdi, et al. "The Role of BRAF V600E Mutation as a Potential Marker for Prognostic Stratification of Papillary Thyroid Carcinoma: a Long-term Follow-up Study." Endocrine Research, vol. 39, no. 4, 2014, pp. 189-93.
Daliri M, Abbaszadegan MR, Bahar MM, et al. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study. Endocr Res. 2014;39(4):189-93.
Daliri, M., Abbaszadegan, M. R., Bahar, M. M., Arabi, A., Yadollahi, M., Ghafari, A., Taghehchian, N., & Zakavi, S. R. (2014). The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study. Endocrine Research, 39(4), 189-93. https://doi.org/10.3109/07435800.2013.879169
Daliri M, et al. The Role of BRAF V600E Mutation as a Potential Marker for Prognostic Stratification of Papillary Thyroid Carcinoma: a Long-term Follow-up Study. Endocr Res. 2014;39(4):189-93. PubMed PMID: 24679337.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study. AU - Daliri,Mahdi, AU - Abbaszadegan,Mohammad Reza, AU - Bahar,Mostafa Mehrabi, AU - Arabi,Azadeh, AU - Yadollahi,Mona, AU - Ghafari,Azar, AU - Taghehchian,Negin, AU - Zakavi,Seyed Rasoul, Y1 - 2014/03/28/ PY - 2014/4/1/entrez PY - 2014/4/1/pubmed PY - 2015/6/13/medline KW - BRAFV600E KW - genetic KW - mutation KW - papillary cancer KW - prognosis KW - thyroid SP - 189 EP - 93 JF - Endocrine research JO - Endocr. Res. VL - 39 IS - 4 N2 - Abstract Papillary carcinoma is the most prevalent malignancy of thyroid gland, and its incidence has been recently increased. The BRAF(V600E) mutation is the most frequent genetic alteration in papillary thyroid carcinoma (PTC). The role of BRAF(V600E) mutation as a potential prognostic factor has been controversially reported in different studies, with short-term follow-up. In this study, we evaluated the role of BRAF(V600E) mutation as a potential marker for prognostic stratification of patients with PTC in long-term follow-up. We studied 69 PTC patients with a mean follow-up period of 63.9 months (median: 60 m). The BRAF(V600E) mutation was analyzed by PCR-single-strand conformational polymorphism and sequencing. The correlation between the presence or absence of the BRAF(V600E) mutation, clinicopathological features and prognosis of PTC patients were studied. The BRAF(V600E) mutation was found in 28 of 69 (40.6%) PTC patients, and it was significantly more frequent in older patients (p < 0.001), in advanced tumor stages (p = 0.006) and in patients with history of radiation exposure (p = 0.037). Incomplete response to treatment in PTC patients was significantly correlated with certain clinicopathological characteristics (follow-up time, distant metastases, advanced stage, first thyroglobulin (fTg) level, history of reoperation and external radiotherapy and delay in iodine therapy) but it was not related to the presence of BRAF(V600E) mutation. Prevalence of BRAF(V600E) mutation was 40.6% in patients with papillary thyroid cancer in northeast of Iran. The BRAF(V600E) mutation was associated with older age and advanced tumor stage but was not correlated with incomplete response during follow-up. SN - 1532-4206 UR - https://www.unboundmedicine.com/medline/citation/24679337/The_role_of_BRAF_V600E_mutation_as_a_potential_marker_for_prognostic_stratification_of_papillary_thyroid_carcinoma:_a_long_term_follow_up_study_ L2 - http://www.tandfonline.com/doi/full/10.3109/07435800.2013.879169 DB - PRIME DP - Unbound Medicine ER -